(Q34571978)

3 August 2017

1 reference

title

The use of dendritic cells in cancer therapy (English)

1 reference

3 August 2017

1 reference

M Jefford

1

0 references

author name string

E Maraskovsky

series ordinal

2

1 reference

PubMed ID

11905751

3 August 2017

J Cebon

series ordinal

3

1 reference

PubMed ID

11905751

3 August 2017

I D Davis

series ordinal

4

1 reference

3 August 2017

1 June 2001

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

343-353

1 reference

3 August 2017

6

1 reference

Dendritic cells and the control of immunity

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Dendritic cell development: multiple pathways to nature's adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Reciprocal control of T helper cell and dendritic cell differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Generation of dendritic cells from fresh and frozen cord blood CD34+ cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Proliferating dendritic cell progenitors in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Immune response against tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Generation of antigen-specific CD4+ T cell lines from naive precursors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Major histocompatibility complex expression on human, male germ cells: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Not just an antigen-presenting cell: 5th international symposium on dendritic cells in fundamental and clinical immunology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Follow-up evaluation of a phase II prostate cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Melanoma vaccines: the paradox of T cell activation without clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Fusion induces tumour rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Dendritic cells or their exosomes are effective biotherapies of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Tolerance, danger, and the extended family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

The Labyrinthine Ways of Cancer Immunotherapy–T Cell, Tumor Cell Encounter: “How Do I Lose Thee? Let Me Count the Ways”

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900389-2

7 January 2021

10.1016/S1470-2045(00)00389-2

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11905751